Posts

Posted on

Engine Capital Concludes Campaign at Lyft Following Productive Engagement on Capital Allocation Initiatives

Engine Capital Concludes Campaign at Lyft Following Productive Engagement on Capital Allocation Initiatives

NEW YORK–(BUSINESS WIRE)–
Engine Capital LP (together with its affiliates, “Engine” or “we”) today announced that it is withdrawing its nomination of candidates for election to Lyft, Inc.’s (NASDAQ: LYFT) (“Lyft” or the “Company”) Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders following its engagement with the Company.

Arnaud Ajdler, Founder and Portfolio Manager of Engine, commented:

“We appreciate the Board’s willingness to engage with us about steps that can be taken to enhance value for all of Lyft’s shareholders. Following a series of productive conversations, the Board has taken an important first step by committing to significant share repurchases in the coming quarters. In light of these actions, we have withdrawn our nomination and are providing the Company time to execute on its new commitments. Engine looks forward to continuing to engage with the Board about additional actions that can benefit shareholders.”

About Engine Capital

Engine Capital LP is a value-oriented special situations fund that invests both actively and passively in companies undergoing change.

For Investors:

Engine Capital LP

212-321-0048

[email protected]

For Media:

Longacre Square Partners LLC

Greg Marose / Bela Kirpalani, 646-386-0091

[email protected] / [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Transport Finance Other Transport

MEDIA:

Posted on

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

  • Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals”, “Conduit” or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases. This approval follows recent grants in the U.S., Japan and Australia and further strengthens Conduit’s global intellectual property position as it advances out-licensing discussions. Notably, South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, making this an important strategic milestone in expanding Conduit’s reach across a highly valuable Asia-Pacific pharmaceutical region.

“The approval from the Korean Intellectual Property Office represents another key milestone in our IP strategy,” said Dr. Andrew Regan, Chief Executive Officer of Conduit Pharmaceuticals. “With growing international patent coverage for AZD1656, we are continuing to build a strong foundation for global partnerships and long-term value creation.”

About Conduit Pharmaceuticals

Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of executives including Dr. Andrew Regan and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit’s future results of operations and financial position, Conduit’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under “Risk Factors” therein, and in other filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.

Investors & Media:

[email protected] 



Posted on

Universal Display Corporation to Exhibit and Present at SID Display Week 2025

Universal Display Corporation to Exhibit and Present at SID Display Week 2025

EWING, N.J.–(BUSINESS WIRE)–Universal Display Corporation (UDC) (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that the Company will exhibit and present at the Society for Information Display (SID) Display Week 2025, a globally recognized symposium and exhibition spotlighting the latest in electronic display and imaging technology, being held May 11-16 in San Jose, California.

“We are pleased to participate in Display Week 2025 and showcase our Company’s breakthroughs and accomplishments in advancing the forefront of OLED materials and technologies,” said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation. “At this year’s event, we will highlight how our broadening portfolio of OLED technologies and phosphorescent materials are driving forward new levels of display energy efficiency and lifetime. Our longstanding track record of delivering cutting-edge and next-gen innovations is built on decades of pushing boundaries, industry leadership and unparalleled OLED expertise and know-how. From our early inventions of stacked OLED (also referred to in the industry as “tandem”), flexible OLED (FOLED), and transparent OLED (TOLED), to the trailblazing discovery of triplet emission, to our current R&D initiatives, including our proprietary Plasmonic PHOLED device architecture, we are innovators elevating OLED performance to new heights. We invite attendees to visit booth #323 and see how our pioneering work is continuing to support the growing OLED industry.”

SID Display Week’s Symposium will include a variety of technical and business events featuring UDC, including:

  • SID/DSCC Business Conference, where Dr. Mike Hack will present on Energy Efficient Phosphorescent OLEDs for a Sustainable Tomorrow on Tuesday, May 13, at 2:45 p.m. PT
  • Session 13: OLED Devices II, where Dr. Haonan Zhao will present his UDC-sponsored research at the University of Michigan on Closing the Reliability Gap Between Blue and Green Phosphorescent Organic Light-Emitting Devices Using the Double-Sided Polariton-Enhanced Purcell Effect on Tuesday, May 13, 2025, at 3:00 p.m. PT
  • Session 20: OLED Common Layer Materials, where Dr. Nicholas Thompson will be the Session Chair on Tuesday, May 13, 2025, at 3:40 p.m. PT
  • Session 50: Automotive Display Performance Improvements, where Dr. Eric Margulies will be the Session Chair on Thursday, May 15, 2025, at 9:00 a.m. PT
  • Session 70: Reliable Oxide TFTs, where Dr. Mike Hack will be the Session Chair on Thursday, May 15, 2025, at 3:10 p.m. PT
  • Poster Session: Dr. Haonan Zhao, will present a poster on his UDC-sponsored research at the University of Michigan, Enhancing the Stability of Deep Blue Phosphor-Sensitized Fluorescent OLED Using Polariton-Enhanced Purcell Effect, on Thursday, May 15, 2025, at 4:30 p.m. PT

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 6,500 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other Company, brand or product names may be trademarks or registered trademarks.

All statements in this document that are not historical, such as those relating to the projected adoption, development and advancement of the Company’s technologies, and the Company’s expected results, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2024. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

Follow Universal Display Corporation

X

Facebook

YouTube

(OLED-C)

Universal Display Contact:

Darice Liu

[email protected]

[email protected]

+1 609-964-5123

KEYWORDS: United States North America California New Jersey

INDUSTRY KEYWORDS: Consumer Electronics Technology Professional Services Semiconductor Research Nanotechnology Alternative Energy Energy Science Hardware Finance

MEDIA:

Logo
Logo
Posted on

Chewy Announces Fiscal First Quarter 2025 Financial Results Conference Call

Chewy Announces Fiscal First Quarter 2025 Financial Results Conference Call

PLANTATION, Fla.–(BUSINESS WIRE)–
Chewy, Inc. (NYSE: CHWY) (“Chewy”), a trusted destination for pet parents and partners everywhere, announced today that it will report fiscal first quarter 2025 financial results before the market opens on Wednesday, June 11, 2025. Management will host a conference call and webcast to discuss the company’s financial results at 8:00 am ET.

To access the conference call by phone, please visit this link for registration (Phone Registration Link) to be provided with dial in details, including a unique PIN to access the conference call. To avoid delays, we encourage participants to register in advance or at a minimum 15 minutes before the start of the call.

A live audio webcast can be accessed on the company’s investor relations website at https://investor.chewy.com and a replay of the conference call will also be available on the company’s investor relations website for at least 90 days following the event.

Chewy Fiscal First Quarter 2025 Financial Results Conference Call

When: Wednesday, June 11, 2025

Time: 8:00 am ET

Live webcast and replay: https://investor.chewy.com

Conference call registration: Phone Registration Link

About Chewy

Our mission is to be the most trusted and convenient destination for pet parents and partners everywhere. We believe that we are the preeminent online source for pet products, supplies and prescriptions as a result of our broad selection of high-quality products and services, which we offer at competitive prices and deliver with an exceptional level of care and a personal touch to build brand loyalty and drive repeat purchasing. We seek to continually develop innovative ways for our customers to engage with us, as our websites and mobile applications allow our pet parents to manage their pets’ health, wellness, and merchandise needs, while enabling them to conveniently shop for our products. We partner with approximately 3,200 of the best and most trusted brands in the pet industry, and we create and offer our own private brands. Through our websites and mobile applications, we offer our customers approximately 130,000 products and services offerings, to bring what we believe is a high-bar, customer-centric experience to our customers.

Investor Contact:

[email protected]

Media Contact:

Diane Pelkey

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Retail Health Other Consumer Consumer Other Retail Pets Veterinary

MEDIA:

Logo
Logo
Posted on

Ritchie Bros. Sells CA$224+ Million of Heavy Equipment Assets and Vehicles at Premier Canadian Auction Event

Ritchie Bros. Sells CA$224+ Million of Heavy Equipment Assets and Vehicles at Premier Canadian Auction Event

EDMONTON, Alberta & WESTCHESTER, Ill.–(BUSINESS WIRE)–
RB Global, Inc. (NYSE: RBA) (TSX: RBA), the trusted global marketplace for insights, services and transaction solutions for commercial assets and vehicles, today announced Ritchie Bros. Auctioneers sold 11,000+ equipment items, trucks and vehicles at its premier Canadian auction event in Edmonton, AB, last week. The five-day auction generated nearly CA$225 million in gross transaction value (GTV).

The April 29 – May 3, 2025, online and onsite auction attracted more than 18,000 bidders from more than 50 countries, with approximately 94% of the equipment selling to Canadians, including 62% purchased by Albertans. The remaining 6% of the equipment was purchased by international buyers from as far away as Saudi Arabia, Egypt, Peru and the Netherlands.

“This year’s April-May event in Edmonton was once again embraced by our many trusted consignors and buyers as the premier event in Canada to buy and sell heavy equipment. In the face of ongoing market uncertainty, Ritchie Bros. once again delivered strong buyer demand on a huge selection of late-model, low-hour equipment,” said Jake Lawson, President of North American Sales for Ritchie Bros. “It is with tremendous pride that we get to host this event every year and we would like to thank the 1,700+ consignors and 4,300+ buyers that contributed to making the 2025 version of it a success.

“We would also like to recognize the generosity of our customers that contributed to raising over $66,000 for charity at our annual customer appreciation event hosted in conjunction with this auction. Together, in the last eight years we have raised $232,000 for the Make-A-Wish Foundation. This year we also proudly raised $33,000 for the Leduc and District Food Bank and Holiday Hampers.”

Ritchie Bros. has more than 80,000 equipment items and trucks in its upcoming auctions and online marketplaces, including 4,800+ items selling in an Ontario Regional Event on May 21–23; 2,900+ items selling in a Quebec Regional Event May 27–29; 1,500+ items selling in an Atlantic Regional Event on May 30; and 1,200+ items selling in a BC Regional Event June 3–4. The next large sale in Edmonton will be June 23–25, with 1,600+ items already listed on the auction site. For a complete list of upcoming auctions and events, including weekly IronPlanet auctions and Marketplace-E events, visit rbauction.com/auctions.

About RB Global

RB Global, Inc. (NYSE: RBA) (TSX: RBA) is a leading, omnichannel marketplace and trusted provider of value-added insights, services and transaction solutions for buyers and sellers of commercial assets and vehicles worldwide. Through its global network of auction sites and digital platform, RB Global serves customers worldwide across a variety of asset classes, including automotive, construction, commercial transportation, government surplus, lifting and material handling, energy, mining and agriculture. The company’s end-to-end marketplace solutions include Ritchie Bros., IAA, Rouse Services, SmartEquip and VeriTread. For more information about RB Global, visit www.rbglobal.com.

Forward-Looking Statements

Certain statements contained in this release include “forward-looking statements” within the meaning of U.S. federal securities laws and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements herein include, in particular, statements relating to the upcoming auctions (including the Ontario, Quebec, Atlantic, and BC Regional Events), and other subjects of this release that are not historical facts. Forward-looking statements are typically identified by such words as “aim”, “anticipate”, “believe”, “could”, “continue”, “estimate”, “expect”, “intend”, “may”, “ongoing”, “plan”, “potential”, “predict”, “will”, “should”, “would”, “could”, “likely”, “generally”, “future”, “long-term”, or the negative of these terms, and similar expressions intended to identify forward-looking statements. It is uncertain whether any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what impact they will have on the results of operations and financial condition of RB Global’s common shares. Therefore, you should not place undue reliance on any such forward-looking statements and caution must be exercised in relying on forward-looking statements. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties that may cause actual results to differ materially, including but not limited to risks and uncertainties relating to: our ability to drive shareholder value; potential growth and market opportunities; the level of participation in our auctions and the success of our online marketplaces; our ability to grow our businesses, acquire new customers, enhance our sector reach, drive geographic depth, and scale our operations; the impact of our initiatives, services, investments, and acquisitions on us and our customers; the acquisition or disposition of properties; potential future mergers and acquisitions; our ability to integrate acquisitions; our future capital expenditures and returns on those expenditures; our ability to add new business and information solutions, including, among others, our ability to maximize and integrate technology to enhance our existing services and support additional value-added service offerings; the supply trend of equipment and vehicles in the market and the anticipated price environment, as well as the resulting effect on our business and Gross Transaction Value (“GTV”); our compliance with laws, rules, regulations, and requirements that affect our business; effects of various economic, financial, industry, and market conditions or policies, including inflation, the supply and demand for property, equipment, or natural resources; the behavior of commercial assets and vehicle pricing; the relative percentage of GTV represented by straight commission or underwritten (guarantee and inventory) contracts, and its impact on revenues and profitability; our future capital expenditures and returns on those expenditures; the effect of any currency exchange and interest rate fluctuations on our results of operations; the effect of any tariffs on our results of operations; the grant and satisfaction of equity awards pursuant to our compensation plans; any future declaration and payment of dividends, including the tax treatment of any such dividends; financing available to us from our credit facilities or other sources, our ability to refinance borrowings, and the sufficiency of our working capital to meet our financial needs; our ability to satisfy our present operating requirements and fund future growth through existing working capital, credit facilities and debt; misappropriation of data or cybersecurity incidents; and, failure to comply with privacy and data protection laws. Other risks that could cause actual results to differ materially from those described in the forward-looking statements are included in “Part I, Item 1A: Risk Factors”, and the section titled “Summary of Risk Factors”, in our Annual Report on Form 10-K for the year ended December 31, 2024, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission, including subsequent Quarterly Reports on Form 10-Q The forward-looking statements included in this release are made only as of the date hereof. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Many of these risk factors are outside of our control, and as such, they involve risks which are not currently known that could cause actual results to differ materially from those discussed or implied herein. RB Global does not undertake any obligation to update any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made, except as required by law.

RB Global Contacts


Media Inquiries:

Val Alitovska | RB Global, Inc.

Director, Corporate Communications

(312) 505-9900

[email protected]

Analyst Inquiries:

Sameer Rathod | RB Global, Inc.

VP, Investor Relations/Market Intelligence

(510) 381-7584

[email protected]

KEYWORDS: United States North America Canada Illinois

INDUSTRY KEYWORDS: Other Retail Online Retail General Automotive Other Construction & Property Aftermarket Automotive Other Manufacturing Construction & Property Other Transport Retail Transport Automotive Manufacturing Manufacturing

MEDIA:

Logo
Logo
Posted on

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast

FREMONT, Calif.–(BUSINESS WIRE)–
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET.

Teleconference Details:

Toll Free: 1-877-407-0779

International: 1-201-389-0914

Conference ID: 13753498

Webcast Link

https://viavid.webcasts.com/starthere.jsp?ei=1717125&tp_key=322c3ca4f6

About Tivic Health Systems, Inc.

Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health’s bioelectronic program is developing non-invasive medical devices that personalize key stimulation parameters for the vagus nerve to deliver meaningfully improved effects on measures of the autonomous nervous system compared to current treatments, which are often invasive, ineffective or both.

Tivic Health’s biopharma program’s lead product candidate is the TLR5 agonist,Entolimod™, which is in late-stage studies to treat acute radiation syndrome (ARS). The FDA has grantedFast TrackandOrphan Drugdesignation to Entolimod™ for ARS. Tivic is also preparing to file an investigational new drug (IND) application and to initiate a phase 2 clinical study for Entolimod™ for the treatment of neutropenia.

TLRs are a class of protein that plays a key role in the innate immune system. We believe that Entolimod’s mechanism of action provides unique, highly sought-after attributes in the treatment of indications in addition to ARS and neutropenia. Tivic Health has the option to license three additional indications: lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome.

Tivic Health already has an FDA-approved over-the-counter device, ClearUP®, that treats sinus pain and pressure and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: https://ir.tivichealth.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks anduncertainties. All statements, other than statements of historical fact, contained in this press release areforward-looking statements. Forward-looking statements contained in this press release may beidentified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,”“should,” “will,” “would,” or the negative of these words or other similar expressions, although not allforward-looking statements contain these words. Forward-looking statements are based on Tivic HealthSystems Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptionsthat are difficult to predict. Further, certain forward-looking statements are based on assumptions as tofuture events that may not prove to be accurate, including as a result of Tivic Health’s interactions with and guidance from the FDA; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; the company’s future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company’s business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company’s need for, and ability to secure when needed, additional working capital; and the company’s ability to maintain its Nasdaq listing. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading “Risk Factors”, as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.

Investor Contact:

Hanover International, Inc.

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Neurology Radiology Biotechnology Pharmaceutical Health Medical Devices Infectious Diseases Health Technology

MEDIA:

Logo
Logo
Posted on

FICO Partner Awards Demonstrate Power of Advanced Analytics Solutions

FICO Partner Awards Demonstrate Power of Advanced Analytics Solutions

Fujitsu, LexisNexis, TCS, TSYS, Dock and Fiserv recognized for bringing outstanding value to business customers worldwide

HOLLYWOOD, Fla.–(BUSINESS WIRE)–FICO World 25 – At its annual FICO® World conference today, global analytics software leader FICO announced the winners of its second FICO® Partner Awards. These six awards recognize firms that are delivering outstanding value to their business customers using FICO® Platform.

More information: https://www.fico.com/en/partner-portal

“Our partners continue to thrill us with their commitment, their innovation and their vision for the future,” said Alexandre Graff, vice president for global partners and alliances at FICO. “These awards celebrate impressive achievements, and they are just a glimpse of the creative work we and our partners are doing to drive outstanding business results for our joint customers.”

The winners are:

New Partner Award: Fujitsu

Fujitsu and FICO began working together in September 2024. The partnership will bring to that market FICO® Platform, as well as FICO solutions for optimization, customer communications and fraud management. Fujitsu also plans to integrate FICO Platform components in its solutions, designed to help customers grow their businesses and solve societal issues. A dedicated team from Fujitsu is committed to position FICO Platform as the engine of digital transformation and financial industries’ modernization in Japan.

Platform Award: TSYS

As a long-standing and trusted partner for three decades, TSYS, a global payments company, continues to invest in new FICO technologies, ensuring their clients benefit from cutting-edge solutions, particularly through their adoption of FICO’s latest customer management solution. By leveraging FICO® Strategy Director, powered by FICO® Platform, TSYS demonstrated an innovative approach to delivering exceptional solutions and value to their clients.

Fraud Fighting Award: Fiserv

With more than 30 years of partnership, FICO and Fiserv have delivered innovative solutions throughout the financial industry. This award celebrates Fiserv’s exceptional commitment to combating fraud and protecting financial institutions and their customers. Leveraging FICO technologies combined with Fiserv’s expertise, Fiserv’s dedication to staying ahead of emerging threats has positioned them as a leader in the fraud prevention space.

Financial Inclusion Award: Dock

Dock, a strategic partner of FICO in Latin America for more than five years, has positioned itself as a key player in promoting financial inclusion. By developing financial solutions integrated with FICO technologies for fraud management, omnichannel communications and authorizations, Dock enables more than 200 clients to increase consumers’ confidence in digital banking solutions, part of expanding financial inclusion.

Innovation Award: TCS

Natural catastrophes have wide ranging impacts across the economy, extending beyond insurance and banking to industries like construction, telecommunications, and manufacturing. Currently, credit ratings used to assess financial risks do not adequately consider climate risks. This miscalculation has led insurers and lenders to avoid certain areas altogether. To address this multibillion-dollar issue, TCS has partnered with FICO and other innovators to provide enhanced climate risk assessment tools for financial decision makers across various sectors. This collaboration will help CFOs, Chief Risk Officers, portfolio managers, underwriters and lenders more accurately assess climate related risks, and simulate the financial impact of the decisions they are making.

Early Marketplace Adopter Award: LexisNexis® Risk Solutions

Following nearly a decade of working with FICO, LexisNexis® Risk Solutions was a natural choice as an early adopter when FICO set out to launch FICO® Marketplace. Their commitment to innovation and a shared vision for growth have made them a key FICO Marketplace provider, providing data sources through FICO’s new B2B exchange for decision assets. LexisNexis® Risk Solutions harnesses the power of data, sophisticated analytics platforms and technology solutions to provide insights that help businesses across multiple industries and governmental entities reduce risk and improve decisions to benefit people around the globe.

About FICO

FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting 4 billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency.

Learn more at https://www.fico.com

Join the conversation at https://x.com/FICO_corp & https://www.fico.com/blogs/

For FICO news and media resources, visit https://www.fico.com/newsroom

FICO is a registered trademark of Fair Isaac Corporation in the U.S. and other countries.

Julie Huang

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Apps/Applications Technology Finance Security Fintech Professional Services Software Data Analytics Data Management

MEDIA:

Posted on

Regions Financial Corporation Announces Redemption of All Outstanding Depositary Shares Representing Interests in Series D Preferred Stock

Regions Financial Corporation Announces Redemption of All Outstanding Depositary Shares Representing Interests in Series D Preferred Stock

All 350,000 Depositary Shares will be redeemed at a redemption price of $1,000 per Depositary Share on June 16, 2025.

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
Regions Financial Corporation today announced the redemption on June 16, 2025, (the “Redemption Date”) of 350,000 depositary shares (CUSIP: 7591EP AR1; ISIN: US7591EPAR12) (the “Depositary Shares”) representing interests in Regions’ Non-Cumulative Perpetual Preferred Stock, Series D (the “Series D Preferred Stock”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508404037/en/

Regions Financial Corp. headquarters in Birmingham, Ala.

Regions Financial Corp. headquarters in Birmingham, Ala.

Each Depositary Share represents a 1/100th interest in a share of the Series D Preferred Stock. All 350,000 Depositary Shares currently outstanding will be redeemed on the Redemption Date. On and after the Redemption Date, no Depositary Shares or shares of Series D Preferred Stock will remain outstanding, and dividends in respect of the Series D Preferred Stock will no longer accrue.

The Depositary Shares will be redeemed at a redemption price of $1,000 per Depositary Share (equivalent to $100,000 per share of Series D Preferred Stock) (the “Redemption Price”). The regular quarterly dividend on the Depositary Shares was separately declared and will be paid immediately prior to the redemption of the Depositary Shares on the Redemption Date to holders of record on the record date for such dividend payment in the customary manner. Accordingly, the Redemption Price does not include any accrued and unpaid dividends.

Simultaneously with the redemption of the Series D Preferred Stock, the outstanding Depositary Shares will be redeemed on the Redemption Date in accordance with the applicable procedures of Broadridge Corporate Issuer Solutions, LLC (“Broadridge”), for an amount per Depositary Share equal to the Redemption Price. All Depositary Shares are held in book-entry form through Broadridge. Broadridge’s contact information is as follows:

51 Mercedes Way

Edgewood, NY 11717

1-631-392-5830

Investors in the Depositary Shares should contact the bank or broker through which they hold a beneficial interest in the Depositary Shares for information about obtaining the Redemption Price for the shares of Depositary Shares in which they have a beneficial interest.

About Regions Financial Corporation

Regions Financial Corporation (NYSE:RF), with $160 billion in assets, is a member of the S&P 500 Index and is one of the nation’s largest full-service providers of consumer and commercial banking, wealth management, and mortgage products and services. Regions serves customers across the South, Midwest and Texas, and through its subsidiary, Regions Bank, operates approximately 1,250 banking offices and more than 2,000 ATMs. Regions Bank is an Equal Housing Lender and Member FDIC. Additional information about Regions and its full line of products and services can be found at www.regions.com.

Forward-Looking Statements

This release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, which reflect Regions’ current views with respect to future events and financial performance. The words “future,” “anticipates,” “assumes,” “intends,” “plans,” “seeks,” “believes,” “predicts,” “potential,” “objectives,” “estimates,” “expects,” “targets,” “projects,” “outlook,” “forecast,” “would,” “will,” “may,” “might,” “could,” “should,” “can,” and similar expressions often signify forward-looking statements. Forward-looking statements are not based on historical information, but rather are related to future operations, strategies, financial results, or other developments. Forward-looking statements are based on management’s expectations as well as certain assumptions and estimates made by, and information available to, management at the time the statements are made, and are subject to various known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from the views, beliefs, and projections expressed in such statements. Factors that may cause actual results to differ from those described in forward-looking statements include those risks and other factors identified in Regions’ Annual Report on Form 10-K for the year ended December 31, 2024, and in Regions’ subsequent filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements, which speak only as of the date made. Regions assumes no obligation and does not intend to update or revise any forward-looking statements that are made from time to time.

Media Contact:

Jeremy D. King

Regions Bank

Regions News Online: regions.doingmoretoday.com

Regions Media Line: (205) 264-4551

KEYWORDS: United States North America Alabama

INDUSTRY KEYWORDS: Finance Business Banking Professional Services Asset Management

MEDIA:

Photo
Photo
Regions Financial Corp. headquarters in Birmingham, Ala.
Logo
Logo
Posted on

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

SOMERVILLE, Mass.–(BUSINESS WIRE)–
bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025.

Stockholders that hold shares of bluebird common stock through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now.

Every share tendered by stockholders is important and it is important to tender now. If a majority of the outstanding shares of bluebird common stock are not tendered, the tender offer will not be completed, and bluebird will not be acquired, putting bluebird at significant risk of defaulting on its loan agreements with Hercules Capital and being forced into bankruptcy or liquidation. It is extremely unlikely that stockholders would receive any consideration for their shares in bankruptcy or liquidation.

Stockholders who need assistance tendering their shares of common stock of bluebird may contact the Information Agent, Innisfree M&A Incorporated, by calling toll-free at (877) 825-8793.

About bluebird bio

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, ß-thalassemia, and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

This communication is not an offer to buy nor a solicitation of an offer to sell any securities of bluebird. The solicitation and the offer to buy shares of bluebird’s common stock is being made pursuant to a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials, that were filed by Beacon Parent Holdings, L.P. (“Parent”) and Beacon Merger Sub, Inc. (“Merger Sub”) with the SEC on March 7, 2025. In addition, bluebird has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer with the SEC on March 7, 2025. The tender offer materials and the Solicitation/Recommendation statement, as they may be amended from time to time, contain important information that should be read carefully when they become available and considered before any decision is made with respect to the tender offer. Investors will be able to obtain a free copy of these materials and other documents filed by Parent, Merger Sub and bluebird with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, copies of these materials and other documents by calling Innisfree M&A Incorporated, the information agent for the Offer, toll-free at (877) 825-8793 for stockholders or by calling collect at (212) 750-5833 for banks or brokers.

INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS, INCLUDING THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 OF BLUEBIRD AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.

Forward-Looking Statements

The statements included in this communication that are not a description of historical facts are forward-looking statements. Words or phrases such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” or similar expressions are intended to identify forward-looking statements. The forward-looking statements are based on bluebird’s current beliefs and expectations and include, but are not limited to: statements regarding beliefs about the potential benefits of the transaction contemplated by the Agreement and Plan of Merger, dated as of February 21, 2025 (the “Merger Agreement”), by and among bluebird, Parent and Merger Sub; the planned completion and timing of the transaction contemplated by the Merger Agreement; statements regarding bluebird’s future results of operations and financial position; bluebird’s expectations with respect to the commercialization of its products, including without limitation, patient demand, the timing and amount of revenue recognition; and bluebird’s ability to establish favorable coverage for its therapies. Risks and uncertainties that could cause results to differ from expectations include: uncertainties as to the timing and completion of the offer and the merger; uncertainties as to the percentage of bluebird stockholders tendering their shares in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the offer or the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable regulatory and/or governmental entities (or any conditions, limitations or restrictions placed on such approvals); risks relating to bluebird’s liquidity during the pendency of the offer and the merger or in the event of a termination of the Merger Agreement; risks that the milestone related to the contingent value right is not achieved; the effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; risks related to diverting management’s attention from bluebird’s ongoing business operations; the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; delays and challenges in bluebird’s commercialization and manufacturing of its products, including challenges in manufacturing vector for ZYNTEGLO and SKYSONA to meet current demand; the internal and external costs required for bluebird’s ongoing and planned activities, and the resulting impact on expense and use of cash, has been, and may in the future be, higher than expected, which has caused bluebird, and may in the future cause bluebird, to use cash more quickly than it expects or change or curtail some of its plans or both; substantial doubt exists regarding bluebird’s ability to continue as a going concern; bluebird’s expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than bluebird’s assumptions; the risk that additional funding may not be available on acceptable terms, or at all; risks related to bluebird’s loan agreement, including the risk that operating restrictions could adversely affect bluebird’s ability to conduct its business, the risk that bluebird will not achieve milestones required to access future tranches under the agreement, and the risk that bluebird will fail to comply with covenants under the agreement, including with respect to required cash and revenue levels, which could result in an event of default; the risk that the efficacy and safety results from bluebird’s prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that the QTCs experience delays in their ability to enroll or treat patients; the risk that bluebird experiences delays in establishing operational readiness across its supply chain; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of bluebird’s therapies; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; the risk that bluebird’s products, including LYFGENIA, will not be successfully commercialized; and other risks and uncertainties pertaining to bluebird’s business, including the risks and uncertainties detailed in bluebird’s prior filings with the SEC, including under the heading “Risk Factors” in bluebird’s Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent Quarterly Reports on Form 10-Q filed with the SEC.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update these statements to reflect events or circumstances after the date hereof, except as required by law.

Investors:

Courtney O’Leary

978-621-7347

[email protected]

Media:

Jess Rowlands

857-299-6103

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Genetics Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo
Posted on

Manhattan Associates Celebrates Seventeenth Consecutive Year as a Leader in the Gartner® Magic Quadrant™ for WMS

Manhattan Associates Celebrates Seventeenth Consecutive Year as a Leader in the Gartner® Magic Quadrant™ for WMS

ATLANTA–(BUSINESS WIRE)–Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, today announced that it has been named a Leader in Gartner® Magic Quadrant™ for Warehouse Management Systems for the 17th time in a row.

Manhattan Active® Warehouse Management is the industry’s first cloud-native WMS, 100% built on microservices to support extensibility and continuous innovation. Its scalable, composable architecture makes it ideally suited to a variety of warehouse settings: from medium complexity operations to the world’s largest, most sophisticated Level 4 and 5 distribution centers.

Beyond the flawless execution of goods and information flows, Manhattan Active WM also delivers improved efficiency and accuracy through automation and streamlined processes, improved real-time visibility and accuracy of inventory levels and locations, enhanced scalability that adapts at pace to changes in demand and business requirements, and labor optimization infused with gamification to create more compelling experiences for warehouse associates.

“We are proud to once again be named a Leader in the Gartner Magic Quadrant for Warehouse Management Systems,” said Adam Kline, senior director of Product Management for Manhattan Associates.

“As an API-first solution, Manhattan Active WM easily integrates with advanced material handling equipment, such as sortation equipment, put walls, automated storage and retrieval systems, as well as the latest robotics and automation solutions. With its ability to work across both automated and manual workflows, balancing efficiency with on-time shipping, Manhattan Active WM is the epitome of future-proof efficiency and agility for modern warehousing, period” continued Kline.

Not only does Manhattan Active WM come with Yard Management and Labor Management baked in, it now incorporates GenAI functionality. Manhattan Active® Assist is a generative AI-powered tool that provides natural language assistance to users of Manhattan’s solutions. It helps answer customer questions in real time and delivers clear, conversational summaries of system configurations—supporting multiple personas, roles, and functions across the organization for more intuitive and efficient interactions.

“Manhattan Active Assist showcases the real-world power of AI in supply chains and logistics and upholds our commitment to ongoing innovation. We believe that this ongoing commitment remains one of the primary reasons Manhattan continues to be the Leader in the WMS space,” Kline concluded.

Backed by the industry’s most-experienced services and support teams, and an extensive ecosystem of global partners, Manhattan Active WM remains a game-changer for any company operating in fast-moving, demanding B2C and B2B environments.

To download a complimentary copy of the 2025 Gartner WMS Magic Quadrant, click HERE.

Receive up-to-date product, customer, and partner news directly from Manhattan Associates on LinkedIn.

Gartner Disclaimer:

GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Manhattan Associates:

Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers. Manhattan Associates designs, builds, and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.

Press Contact:

Devika Goel

Manhattan Associates

[email protected]

 

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Software Data Management Technology Supply Chain Management Logistics/Supply Chain Management Transport Retail Other Technology

MEDIA: